Literature DB >> 16413618

A target on the move: innate and adaptive immune escape strategies of hepatitis C virus.

Robert Thimme1, Volker Lohmann, Friedemann Weber.   

Abstract

Obligate intracellular parasites such as the hepatitis C virus (HCV) have to cope intensively with immune responses in order to establish persistent infection. Powerful antiviral mechanisms of the host act on several levels. The innate immune response is able to slow down viral replication and activate cytokines which trigger the synthesis of antiviral proteins. The adaptive immune system neutralizes virus particles and destroys infected cells. Viruses have therefore developed a number of countermeasures to stay moving targets for the immune system. Here, we attempt to summarize the current state of research regarding innate and adaptive immune responses against HCV and the different escape strategies evolved by this virus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16413618     DOI: 10.1016/j.antiviral.2005.12.001

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  42 in total

Review 1.  Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors.

Authors:  Maya Gambarin-Gelwan; Ira M Jacobson
Journal:  Curr Gastroenterol Rep       Date:  2012-02

2.  Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C.

Authors:  Kuo-Chih Tseng; Yun-Che Ho; Yu-Hsi Hsieh; Ning-Sheng Lai; Zhi-Hong Wen; Chin Li; Shu-Fen Wu
Journal:  J Gastroenterol       Date:  2012-02-28       Impact factor: 7.527

3.  Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model.

Authors:  Hannah Perkins; Tansi Khodai; Houria Mechiche; Peter Colman; Frances Burden; Carl Laxton; Nigel Horscroft; Tom Corey; Deborah Rodrigues; Jaiessh Rawal; Jonathan Heyen; Mark Fidock; Mike Westby; Helen Bright
Journal:  J Clin Immunol       Date:  2012-04-05       Impact factor: 8.317

4.  The induction of type I interferon production in hepatitis C-infected patients.

Authors:  Lawrence M Pfeffer; Margaret A Madey; Caroline A Riely; Jaquelyn F Fleckenstein
Journal:  J Interferon Cytokine Res       Date:  2009-05       Impact factor: 2.607

Review 5.  Regulatory T cells in viral hepatitis.

Authors:  Eva Billerbeck; Tobias Bottler; Robert Thimme
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

Review 6.  Interaction of hepatitis C virus with the type I interferon system.

Authors:  Friedemann Weber
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

7.  Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).

Authors:  Scott D Seiwert; Steven W Andrews; Yutong Jiang; Vladimir Serebryany; Hua Tan; Karl Kossen; P T Ravi Rajagopalan; Shawn Misialek; Sarah K Stevens; Antitsa Stoycheva; Jin Hong; Sharlene R Lim; Xiaoli Qin; Robert Rieger; Kevin R Condroski; Hailong Zhang; Mary Geck Do; Christine Lemieux; Gary P Hingorani; Dylan P Hartley; John A Josey; Lin Pan; Leonid Beigelman; Lawrence M Blatt
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

Review 8.  Immune responses during acute and chronic infection with hepatitis C virus.

Authors:  Shigeaki Ishii; Margaret James Koziel
Journal:  Clin Immunol       Date:  2008-06-02       Impact factor: 3.969

9.  Virus-host coevolution: common patterns of nucleotide motif usage in Flaviviridae and their hosts.

Authors:  Francisco P Lobo; Bruno E F Mota; Sérgio D J Pena; Vasco Azevedo; Andréa M Macedo; Andreas Tauch; Carlos R Machado; Glória R Franco
Journal:  PLoS One       Date:  2009-07-20       Impact factor: 3.240

10.  Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.

Authors:  Ania M Owsianka; Alexander W Tarr; Zhen-Yong Keck; Ta-Kai Li; Jeroen Witteveldt; Richard Adair; Steven K H Foung; Jonathan K Ball; Arvind H Patel
Journal:  J Gen Virol       Date:  2008-03       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.